The atypical subgroup of the protein kinase C (PKC) family of isozymes is composed of two members: /PKC and PKC (1, 33, 38) . PKC is the human homolog of the mouse PKC, and both show a high degree of homology in the catalytic as well as in the regulatory domain with PKC from different species (32) . Of great interest is the fact that both the structure and the mechanism of regulation of the two atypical PKCs by lipid activators differ from those of the other members of their family. Thus, they do not contain the Ca 2ϩ -binding region, and they have only a single zinc finger-like motif, which in other PKC isoforms has been shown to be double and responsible for the activation by diacylglycerol and phorbol esters (32) . Consequently, the atypical PKCs cannot be regulated by Ca , and are insensitive to phorbol esters and diacylglycerol (1, 33, 38, 42) . However, native PKC is activated by critical lipid second messengers like phosphatidic acid (31) and phosphatidylinositol 3,4,5-P 3 (30) . Phosphatidic acid is produced as consequence of the activation of phosphatidylcholine-phospholipase D or the concerted action of phosphatidylcholine-phospholipase C and diacylglycerol kinase (12) . Both phospholipases have been implicated in cell proliferation and tumor transformation (12, 20, 22, 43) . Phosphatidylinositol 3,4,5-P 3 is the product of the phosphoinositide-3 kinase, which constitutes a decisive step during mitogenic signal transduction (41) . On the other hand, ceramide that is generated following the activation of sphingomyelin hydrolysis by inflammatory cytokines, such as interleukin-1 or tumor necrosis factor alpha (TNF-␣) (13, 18) , has been shown to bind and activate PKC (24, 28) . Taken together, all these observations pinpoint to PKC as a target of important lipid second messengers and suggest its role in cell signalling.
Molecular cloning of an atypical PKC isotype from Xenopus laevis with the regulatory domain of rat PKC as a probe produced a cDNA encoding a protein highly homologous to rat PKC, which was the only atypical isotype known at that time (10, 33) . The cloned X. laevis atypical PKC displays an overall 72% identity at the amino acid level to PKC, which becomes 84% in the catalytic domain (10, 33) . This led to the identification of that gene product as the X. laevis PKC (10) . The more recent description of /PKC (1, 38) allowed the comparison of the X. laevis enzyme with all known atypical subspecies. On the basis of alignment of their sequences, the cloned X. laevis atypical PKC shows the highest degree of homology with /PKC, with an overall 90% identity at the amino acid level. Therefore, the cloned X. laevis enzyme is actually /PKC (10) . Interestingly, the pseudosubstrate sequence is identical in both atypical isotypes but is significantly different from that of conventional or novel PKCs (1, 32, 38) . Microinjection of a peptide with the sequence of the pseudosubstrate of the atypical PKC isotypes but not of ␣PKC or εPKC, dramatically inhibited maturation (10) and NF-B (11) activation in X. laevis oocytes, as well as the reinitiation of DNA synthesis in quiescent mouse fibroblasts (3) . This indicates that either or both atypical isoforms are important in mitogenic activation. Besides the pseudosubstrate, the major differences in the sequence between /PKC and PKC are located in the regulatory domain. Therefore, any functional divergence between the two types of atypical PKCs will presumably reside in that region. We reasoned that proteins that interact with the regulatory domain of /PKC but not with PKC could be potential and specific regulators of its enzymatic activity both in vitro and in vivo and that their molecular characterization would help to dissect specific pathways regulating the different atypical isotypes.
MATERIALS AND METHODS
Yeast strains and media. (39) .
Two-hybrid screening and cDNA isolation. For the yeast two-hybrid screening, pYTH9/PKC REG was cotransformed with the human placenta cDNA Matchmaker library in the pGAD10 vector (Clontech Laboratories, Inc.) into the Y190 yeast strain, as described previously (14, 37) , and the transformants were plated to synthetic medium lacking histidine, leucine, and tryptophan but containing 20 mM 3-amino-1,2,4-triazole. The plates were incubated at 30ЊC for 5 days. His ϩ colonies were assayed for ␤-galactosidase activity by a filter assay as described below. To obtain a cDNA for the full-length lambda-interacting protein (LIP) coding sequence, a human placenta 5Ј-RACE-Ready cDNA (Clontech Laboratories, Inc.) was used as the template in PCR with primers RACE1 (5Ј-GCG AATTCTCTGAGTAGACATATCCTGG-3Ј) and anchor (5Ј-CTGGTTCGGC CCACCTCTGAAGGTTCCAGAATCGATAG-3Ј). The conditions of the PCR were 30 cycles of 94ЊC for 45 s, 60ЊC for 45 s, and 72ЊC for 2 min, with a final extension time of 7 min at 72ЊC. For the second 5Ј-RACE reaction, primers RACE2 (5Ј-CTGAATTCTCATGCTGGTTAGGATAGCAG-3Ј) and anchor were used. Oligonucleotides were synthesized by Isogen Biosciences. DNA sequencing was done by the dideoxynucleotide chain termination method.
␤-Galactosidase filter assays. Yeast strains were patched to synthetic medium lacking leucine and tryptophan, incubated for 3 days at 30ЊC, and transferred to a nitrocellulose filter (5) . The filter was placed on aluminum foil atop a sea of liquid nitrogen for 20 s and then immersed in liquid nitrogen for 1 to 2 s. The filter was allowed to come to room temperature and then placed on top of Whatman no. 1 paper that had been prewetted in Z buffer containing 0.75 mg of 5-bromo-4-chloro-3-indolyl-␤-D-galactoside (X-Gal) per ml (25) . The filters were incubated for 3 h at 30ЊC. Blue coloration is indicative of ␤-galactosidase activity.
Plasmids. pYTH9/PKC was constructed from full-length X. laevis PKC derived by PCR (oligonucleotides 5Ј-GCGAATTCCATGCCGACACAGAGG G-3Ј and 5Ј-CGAGGTCGACGGTATCG-3Ј) and the template pBluescript PKC (3) at the EcoRI site of pYTH9. pYTH9/PKC REG was constructed from the regulatory domain of X. laevis PKC (amino acids 1 to 250) and was made in the same way as pYTH9/PKC but with the oligonucleotides 5Ј-GCGAATTC CATGCCGACACAGAGGG-3Ј and 5Ј-TTGGAATTCTCAGCTAGATGGGC TCTTTCCAC-3Ј. pYTH9/PKC REG-C167S was obtained by replacing Cys-167 with a serine residue by PCR-directed mutagenesis. Deletions of the regulatory domain were used to construct pYTH9/PKC 126 (oligonucleotides 5Ј-GCGAA TTCCATGCCGACACAGAGGG-3Ј and 5Ј-GCCGAATTCTCATCCATTTG CACAATAC-3Ј at the EcoRI site of pYTH9) and pYTH9/PKC ZF (oligonucleotides 5Ј-CTGCTCGAGGCTGTATTGTGCAA-3Ј and 5Ј-GCCGAAT TCTCATCCATTTGCACAATAC-3Ј, subcloned into the SalI-EcoRI sites of pYTH9). pYTH9/PKC CAT contains the catalytic domain (oligonucleotides 5Ј-GCGAATTCCTGGGACTCCAAGACTT-3Ј and 5Ј-CGAGGTCGACGGT ATCG-3Ј) at the EcoRI site of pYTH9. pYTH9PKC was constructed from full-length rat brain PKC derived by PCR (oligonucleotides 5Ј-GGAGAATTC CATGCCCAGCAGGACC-3Ј and 5Ј-ATTCCCGGGTCACACGGACTCCT CA-3Ј) at the EcoRI-SmaI sites of pYTH9.pYTH9PKC REG was constructed from the regulatory domain (amino acids 1 to 250) made the same way as pYTH9PKC but with oligonucleotides 5Ј-GGAGAATTCCATGCCCAGCA GGACC-3Ј and 5Ј-AGGAATTCTCACTGAGAGATTTTGATCCCATC-3Ј and with subcloning into the EcoRI site of the same vector. Deletions of the regulatory domain yielded pYTH9PKC 126 (oligonucleotides 5Ј-GGAGAATTC CATGCCCAGCAGGACC-3Ј and 5Ј-TTGGAATTCTCAGCCGTTGGCTCG GTAT-3Ј) and pYTH9PKC ZF (oligonucleotides 5Ј-ATTGAATTCGCTATAC CGAGCCAACGGC-3Ј and 5Ј-GCCGAATTCTCAATCTACTGGAGGCTC TTG-3Ј) at the EcoRI site of pYTH9. pYTH9␣PKC REG CAT , and pGBT9 Mos have been described previously (29) . pGAD10-LIP contains the full-length cDNA LIP and was amplified by PCR with oligonucleotides 5Ј-GCGAATTCAT GCTGCATGAACTGGACGGT-3Ј and 5Ј-CGGAATTCCGAGAATCTGAAT GCAT-3Ј and subcloned into the EcoRI site of pGAD10.
Plasmids GST-/PKC REG , GST-/PKC
126
, and GST-/PKC ZF were generated by PCR with pBluescript-PKC as the template (3) , and GST-PKC ZF were generated by PCR with MBP-PKC as the template (8) and the primers 5Ј-ATTGGATCCAGCAGGACCG ACCCCAA-3Ј and 5Ј-AGGAATTCTCACTGAGAGATTTTGATCCCATC-3Ј for GST-PKC REG , 5Ј-ATTGGATCCAGCAGGACCGACCCCAA-3Ј and 5Ј-TTGGAATTCTCAGCCGTTGGCTCGGTAT-3Ј for GST-PKC
, and 5Ј-AT TGGATCCCTATACCGAGCCAACGGC-3Ј and 5Ј-GCCGAATTCTCAATC TACTGGAGGCTCTTG-3Ј for GST-PKC ZF . The PCR products were digested with BamHI and EcoRI and cloned into BamHI-EcoRI-digested pGEX-2TK. pGEX-2TK constructs were transformed into Escherichia coli JM101, and expression of glutathione-S-transferase (GST) fusion proteins and their purification on glutathione-Sepharose were carried out as specified by the manufacturer. MBP-LIP(R4) contains the partial cDNA clone of LIP inserted in the EcoRI site of pMALc2 (New England Biolabs). The MBP-LIP(R4) fusion protein was expressed in E. coli and purified by binding to an amylose resin as specified by the manufacturer. Expression and purification of hnRNPA1 have been described previously (29) .
To make the HA-tagged plasmids, pCDNA3-HA was constructed as follows. The following pair of complementary oligonucleotides was synthesized, annealed, and ligated into pCDNA3 (Invitrogen) digested with HindIII and EcoRI, to create pCDNA3-HA vector: 5Ј-AGCTTGCCGCCACCATGTATGATGTTCCTGAT TATGCTAGCCTCCCGGGG-3Ј and 5Ј-AATTCCCCGGGAGGCTAGCAT AATCAGGAACATCATACATGGTGGCGGCA-3Ј. To construct pCDNA3-HA-PKC and pCDNA3-HA-PKC MUT , a fragment corresponding to the fulllength wild-type or kinase-inactive mutant of rat brain PKC was obtained by PCR with pBluescriptPKC or pSelectPKC MUT , respectively, as template and with the primers 5Ј-GGAGAATTCCATGCCCAGCAGGACC-3Ј and 5Ј-ATGT CTAGACACGGACTCCTCAGCAGA-3Ј, digested with EcoRI and XbaI, and subcloned into the EcoRI-XbaI sites of pCDNA3-HA. pSelectPKC MUT was derived by directed mutagenesis from pSelectPKC and the mutagenic oligonucleotide 5Ј-GATTTACGCCATGTGGGTGGTGAAGAAGGAGC-3Ј. pSelect PKC was obtained by subcloning the EcoRI fragment containing full-length PKC from pBluescriptPKC into pSelect (Promega). pCDNA3-HA/-PKC and pCDNA3-HA/-PKC MUT were generated by PCR with pBluescript/PKC or pSelect/PKC MUT (3) as the template, respectively, and the primers 5Ј-GCG AATTCCATGCCGACACAGAGGG-3Ј and 5Ј-CGAGGTCGACGGTATCG-3Ј. The PCR products were cut with EcoRI and ligated to pCDNA3HA previously cut with the same enzyme. To obtain the HA-tagged kinase-inactive mutants of /PKC and PKC, CMV-LIP(R4) was generated by PCR with primers 5Ј-TCGAAGCTTATGGGTCTTGAACATCCTAT-3Ј and 5Ј-CGAGAATCTG AATGCAT-3Ј and with pGAD10-LIP(R4), the original clone obtained from the yeast two-hybrid screen, as the template and subcloned into HindIII and XbaI sites of pRcCMV (Invitrogen). All constructs were confirmed by nucleotide sequence analysis, and the expression of the fusion proteins was confirmed by immunoblotting.
Northern (RNA) blots. Samples (10 g) of total RNA from different human tissues (Clontech Laboratories, Inc.) were run on formaldehyde-agarose gels, blotted onto Hybond-N ϩ filters, and hybridized overnight at 42ЊC in 5ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-5ϫ Denhardt's solution (1ϫ Denhardt's solution is 0.02% polyvinylpyrrolidone, 0.02% Ficoll 400, and 0.02% bovine serum albumin)-10 mM Tris-Cl (pH 7.5)-0.5% sodium dodecyl sulfate (SDS) to 50% formamide-200 g of denaturated salmon sperm DNA per ml-50 g of tRNA per ml with a 32 P-labelled cDNA probe of LIP (clone R4). The filters were washed for 15 min at room temperature in 2ϫ SSC, three times (1 h each time) at 56ЊC with 0.1ϫ SSC-0.5% SDS, and 5 min at room temperature with 2ϫ SSC.
In vitro binding studies. GST, GST-/PKC, and GST-PKC were incubated with the resin-bound MBP or MBP-LIP(R4) at the protein concentrations specified in the figure legends. The binding-reaction mixtures contained 85 mM NaCl, 10% glycerol, 0.6 mM guanine nucleotide, and 6 mM free magnesium.
After 60 min at 4ЊC, the resin was sedimented and washed with 0.5 ml (10 bed volumes) of 10 mM Tris-HCl (pH 7.6)-10% glycerol-5 mM MgCl 2 -1 mM dithiothreitol-0.1% Triton X-100-0.1 mM phenylmethylsulfonyl fluoride. The bound proteins were boiled in sample buffer, separated by SDS-polyacrylamide gel electrophoresis (PAGE), transferred, and immunoblotted with an anti-GST antibody (Santa Cruz Biotechnology).
Antibody production and immunoblot analysis. Antibodies against LIP were prepared by immunizing rabbits with the MBP-LIP(R4) fusion protein. For immunoblot analysis, 30 g of cellular protein was resolved in SDS-10% polyacrylamide gels. The protein was then electrophoretically transferred onto a nitrocellulose filter (Promega) and incubated with preimmune serum or anti-LIP antibody. Bands were visualized with the ProtoBlot AP System (Promega).
Transfections. Subconfluent cultures of Cos cells in 100-mm plates were transfected by the calcium phosphate method (Gibco, BRL) with 20 g of either pCDNA3-HA, pCDNA3-HA-/PKC, or pCDNA3-HA-PKC. Plasmid DNA was removed 4 h later, and the cells were incubated for 16 h in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Then, medium was replaced with medium containing 0.5% fetal calf serum and the incubation was continued for 16 h, followed by an additional 8 h in serum-free medium. Cultures were then extracted with lysis buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM ethylene glycol-bis(␤-aminoethyl ether)-N,N,NЈ,NЈ-tetraacetic acid (EGTA), protease inhibitors] and immunoprecipitated with 2 g of anti-HA antibody (12CA5; Boehringer, Mannheim, Germany) per mg of protein extract. Immunoprecipitates were washed seven times with lysis buffer containing 0.5 M NaCl. For the in vitro kinase assay, immunocomplexes were incubated with 1 g of recombinant bacterially produced heterogeneous nuclear ribonucleoprotein A1 (29) in the presence or absence of 1 g of MBP, MBP-LIP(R4), or phosphatidylserine as sonicated vesicles (50 g/ml) and 5 to 10 Ci of [␥- Reactions were stopped by the addition of concentrated sample buffer. Samples were boiled for 3 min and separated by SDS-PAGE followed by autoradiography.
Subconfluent cultures of Cos cells in 100-mm-diameter plates were transfected with 5 g of either pCDNA3-HA, pCDNA3-HA-/PKC, or pCDNA3-HA-PKC together with 20 g of CMV or CMV-LIP(R4). Plasmid DNA was removed 4 h later, and cells were incubated for 16 h in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Then the medium was replaced with medium containing 0.5% fetal calf serum and the incubation was continued for 16 h, followed by an additional 8 h in serum-free medium. Cultures were then either untreated or stimulated with 10% fetal calf serum for 5 min. Immunoprecipitates and kinase assays were performed as above. In another set of experiments, subconfluent cultures of Cos cells were transfected with different amounts of plasmid CMV-LIP(R4) together with 500 ng of 3EConALuc reporter plasmid. In some experiments, these plasmids were cotransfected with 5 g of the different /PKC expression vectors. After 4 h, the DNA-containing medium was removed and cells were made quiescent by serum starvation for 36 h. Then the cells were either untreated or stimulated with human TNF-␣ (500 U/ml) for 6 h as a control, extracts were prepared, and luciferase activity was determined as described previously (2) . Data are expressed in terms of relative luciferase activity units, calculated as (light emission from experimental sample-light emission of lysis buffer alone) per microgram of cellular protein in the sample. In another set of experiments, Cos cells were transfected with the B reporter plasmid with different concentrations of either empty vector or expression plasmids for wild-type and kinase-inactive mutants of /PKC and PKC, and the experiments were processed as above.
In vivo association. Quiescent NIH 3T3 fibroblasts, either untreated or stimulated according to the experiments, or proliferating HeLa cells were extracted with lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM EGTA, 25 g of leupeptin per ml, 25 g of aprotinin per ml, 25 g of pepstatin per ml, and 1 mM phenylmethylsulfonyl fluoride) and immunoprecipitated with an anti-/PKC-PKC antibody (Gibco, BRL) either in the absence or in the presence of competing peptide as described previously (3) . The immunoprecipitates were resolved by SDS-PAGE and immunoblotted with anti-LIP antibody.
Nucleotide sequence accession number. The GenBank accession number of the LIP sequence is U32581.
RESULTS
Functional role of /PKC and PKC. Since transfection of a dominant negative mutant of /PKC (identified as PKC in references 3, 4, 7, and 9) inhibited a number of cell functions including the activation of B-dependent promoters (4, 7), it was of interest to determine whether a dominant negative mutant of PKC similarly affected this parameter. Therefore, either Cos cells (Fig. 1) or NIH 3T3 cells (not shown) were transfected with different concentrations of expression vectors for HA-tagged PKC or /PKC, which were either wild type or dominant negative mutants along with a B-driven reporter plasmid. Interestingly, cotransfection of the wild-type /PKC significantly stimulated the B-dependent promoter activity, with a maximum around 15 g (Fig. 1A) . Transfection of PKC, although significantly less potent at lower concentrations, displayed a similar degree of activation of the reporter at high expression levels (Fig. 1A) . Transfection of dominant negative /PKC severely reduced the activation of this reporter activity, with complete inhibition at around 20 g (Fig.  1B) , whereas a similar level of reduction was obtained with 30 g of the PKC expression vector. Figure 1C shows a representative immunoblot in which the expression levels of the four transfected constructs were very similar. Taken together, these results indicate that although the stimulation of the B-dependent promoter activity appears to be more sensitive to the transfection of /PKC, no obvious differences were observed between the atypical isotypes at higher expression levels. This was as expected, because of the near identity of the catalytic domains of /PKC and PKC. The different sensitivities of the B-dependent promoter activity to low concentrations of /PKC and PKC could be due to the sequence divergences existing in their regulatory domain. The identification of proteins that selectively interact with the regulatory region of /PKC but not with PKC would help us to understand the potential functional and/or regulatory differences between the atypical PKCs.
Yeast two-hybrid screen. To identify potential specific activators of /PKC, the regulatory domain of that kinase (amino acids 1 to 250) was fused with the DNA-binding domain of the yeast GAL4 protein (pYTH9/PKC REG ) to serve as the ''bait'' to screen a human placenta Matchmaker cDNA library. Colonies that grew on yeast dropout media lacking Leu, Trp, and His but containing 20 mM 3-amino-1,2,4-triazole and that were blue when assayed by X-Gal colony filter assay were selected. Twelve positive colonies that stained intensely blue within 20 min were obtained from 2.5 ϫ 10 6 screened. The expression of His-3 and LacZ in these colonies was shown to depend on the GAL4 fusion protein by retransforming the recovered plasmids into yeasts containing the bait construct ( Fig. 2A, a and b ; Table 1 ). The sequences of the 12 clones revealed that they were identical and partial (clone R4; 1,568 bp). To obtain the missing 5Ј region, a human placenta 5Ј-RACE Ready cDNA (Clontech Laboratories, Inc.) was used. This procedure yielded an additional 5Ј fragment of 453 bp. With that sequence, the appropriate oligonucleotide was used in a second 5Ј-RACE reaction, which produced another 1.3-kb fragment, including the initiation codon and some of the 5Ј untranslated region. The resulting full-length cDNA clone encodes for a novel protein of 713 amino acids, with a predicted molecular mass of 79.7 kDa, and with no exact matches in the cDNA and protein data banks searched (Fig. 3) . From now on, this protein will be termed LIP (lambda-interacting protein). Northern blot analysis was done with RNAs derived from different human tissues. LIP appears to be expressed in the placenta, brain, lung, and spleen (Fig. 4) .
Specificity of the interaction of LIP with the /PKC regulatory domain. The specificity of the interaction between /PKC REG and LIP was tested with an unrelated molecule, pYTH9-lamin, which fails to transactivate the reporter constructs ( Fig. 2A, c ; Table 1 ). Of note, the catalytic domain of /PKC did not interact with LIP whereas the full-length protein did show interaction, albeit less strongly than the regulatory region (Fig. 2A, d ) and its ability to interact with LIP in the two-hybrid system was determined. Interestingly, LIP does not interact with the regulatory domain of rat PKC or with the regulatory domains of ␣PKC or εPKC ( Fig. 2A, f ; Table 1 ), indicating that its binding to /PKC is highly specific for this atypical isotype. On the other hand, Raf-1 is a serine/threonine kinase with an overall structure similar to that of the atypical PKCs (33) . Both type of kinases are critical components downstream of Ras in mito-
FIG. 1. Role of /PKC and PKC in the stimulation of B-dependent promoter activity. (A) Cos cells were transfected with different concentrations of either empty plasmid (å) or expression vectors for HA-tagged wild-type /PKC (F) and PKC (s)
, along with 500 ng of the B enhancer-directed luciferase reporter plasmid (3EconALuc). After 4 h, the DNA-containing medium was removed and cells were made quiescent by serum starvation for 24 h. Then extracts were prepared, and the luciferase activity was determined as described in Materials and Methods. As a control, cells transfected with the maximal concentration of empty plasmid were stimulated with TNF-␣ (500 U/ml) for 4 h (empty bar). Results are the mean Ϯ standard deviation (SD) of three independent experiments with incubations in duplicate. (B) Cos cells were transfected with different concentrations of either empty plasmid (F) or expression vectors for HA-tagged kinase-inactive mutants of /PKC (s) and PKC (å), along with 500 ng of the B enhancer-directed luciferase reporter plasmid (3EconALuc). After 4 h, the DNA-containing medium was removed and cells were made quiescent by serum starvation for 24 h. Then cells were stimulated with TNF-␣ (500 U/ml) for 4 h. Extracts were prepared, and the luciferase activity was determined as described in Materials and Methods. Results are the mean Ϯ SD of three independent experiments with incubations in duplicate. ZF (f). Individual Leu ϩ Trp ϩ transformants were streaked to synthetic medium plates lacking tryptophan, leucine, and histidine. The plates were incubated at 30ЊC for 3 days. Essentially identical results were obtained in another two experiments. genic cascades (3, 6, 9, 10, 15-17, 19). Therefore, it was of great interest to determine whether Raf-1 would interact with LIP. The catalytic domain ( Fig. 2A, g; Table 1 ), the full-length Raf-1 ( Fig. 2A, h ; Table 1 ), and the regulatory region ( Fig. 2A,  i ; Table 1 ) of Raf-1 all failed to interact with LIP. The product of c-mos that is another serine/threonine kinase critically involved, like Raf-1 and the atypical PKCs, in mitogenic signal transduction in X. laevis oocytes and mammalian cells (36) did not interact with LIP ( Fig. 2A, j ; Table 1 ). Therefore, these data collectively indicate that LIP specifically binds to the regulatory domain of /PKC but not to other structural and functional related kinases.
LIP binds specifically to the zinc finger of /PKC. To map the region in the regulatory domain of /PKC where LIP binds, cDNA fragments corresponding to amino acids 1 to 126 and amino acids 127 to 194 (corresponding to the zinc finger region) of /PKC and PKC, respectively, were fused with the DNA-binding domain of the yeast GAL4 protein and their ability to interact with LIP in the two-hybrid system was determined. Interestingly, only the zinc finger and the whole regulatory domain of /PKC displayed LIP-binding activity ( Fig. 2B; Table 1 ). No binding was detected with the different PKC fragments or with the region encompassing amino acids 1 to 126 of /PKC ( Fig. 2B; Table 1 ). As an important control, disruption of the cysteine finger by mutation of cysteine 167 to serine in the /PKC regulatory domain completely abolished the binding of LIP (Table 1) . To our knowledge, this is the first report of a protein that interacts with a PKC through the putative zinc finger lipid-binding domain.
LIP interacts with /PKC in vitro and in vivo. To further investigate the interaction between LIP and /PKC, the cloned partial LIP cDNA (clone R4) was expressed as an MBP fusion protein and tested to see if it could interact in vitro with either the region encompassing amino acids 1 to 126, the zinc finger, or the whole regulatory domain of both /PKC and PKC, which have been expressed as GST fusion proteins (Fig.  5A) . Two different concentrations (200 or 400 nM) of MBP or MBP-LIP(R4) were incubated with 800 nM GST fusion proteins for 1 h at 4ЊC, after which MBP and MBP-LIP(R4) were immobilized on amylose resin. Following extensive washing with binding buffer plus 0.1% Triton X-100, bound MBP fusion proteins and any associated proteins were boiled in sample buffer, fractionated by SDS-PAGE, and immunoblotted with anti-GST antibody to detect binding of the different GST fusion proteins to LIP. Of note, GST-/PKC ZF and GST-/ PKC REG but not GST, GST-/PKC 126 , or any GST-PKC fusion proteins bound to MBP-LIP(R4) (Fig. 5B ; data not shown for PKC). Also, no binding of GST-/PKC ZF or GST-/PKC REG to MBP alone was detected (Fig. 5B) . Taken together, these data indicate that LIP specifically binds in vitro to the zinc finger domain of /PKC. Staining of a parallel gel confirmed that all the reactions contained equal molar amounts of GST (Fig. 5C) and MBP (not shown) fusion proteins.
To determine whether LIP and /PKC can also interact in vivo, we next used the MBP-LIP(R4) fusion protein to immunize rabbits and generate an antibody against LIP. This antiserum specifically recognizes a band of 80 kDa in immunoblots of extracts from HeLa cells that is not seen with the preimmune serum. The molecular mass of that band is in good agreement with that predicted from the protein sequence (Fig.  3) . Actively proliferating HeLa cells were immunoprecipitated, either in the absence or in the presence of the competing peptide, with an antibody that recognizes an epitope present in both /PKC and PKC. Immunoprecipitates were then resolved by SDS-PAGE and immunoblotted with anti-LIP antibody. Interestingly, results from Fig. 6A demonstrate that LIP is specifically detected in the immunoprecipitates performed in the absence of competing peptide, indicating the in vivo association of LIP with /PKC and/or PKC in proliferating cells. Since the antibody used during the immunoprecipitation does not discriminate between /PKC and PKC, the interaction between LIP and PKC in vivo cannot be completely ruled out, although the experiments described above and in the next section make this possibility highly unlikely. We next determined whether the association of LIP with /PKC in vivo can be triggered by serum. Quiescent NIH 3T3 cells were stimulated with serum for different times, after which cell lysates were immunoprecipitated with the anti-/PKC-PKC antibody and the immunoprecipitates were analyzed by immunoblotting with anti-LIP antibody, following their fractionation by SDS-PAGE. Of note, quiescent cells displayed little or no binding of LIP to /PKC but their association was dramatically increased by stimulation with serum (Fig. 6B) . This increased activation was maximal by 10 min (Fig. 6B ). All the above data suggest that LIP may be an important regulator of /PKC activity in response to mitogenic activation.
LIP is a potent activator of /PKC but not of PKC in vitro and in vivo. Because LIP binds specifically to the zinc finger of /PKC and that region in classical PKC isoforms has been shown to mediate the binding of stimulants (32, 34) , we sought to determine if the interaction of LIP with /PKC can regulate its enzymatic activity both in vitro and in vivo. Therefore, serum-starved Cos cells were transfected with HA protein epitope-tagged X. laevis /PKC or rat brain PKC and the expressed proteins were immunopurified with the anti-HA monoclonal antibody 12CA5. The addition of phosphatidylserine (a classical activator of all PKCs) to the immunoprecipitates significantly activated both /PKC and PKC (Fig. 7) . Interestingly, the addition of 1 g of MBP-LIP(R4) but not of MBP alone produced a dramatic activation of HA-/PKC but not of PKC, comparable to that produced by phosphatidylserine (Fig. 7) . Therefore, LIP not only binds specifically to 
Ϫ Ϫ a ␤ -Galactosidase activity was determined by a filter assay for the yeast strains containing the indicated plasmids as described in Materials and Methods. Plus signs represent a positive indication of ␤-galactosidase activity (blue color) in filter assays. Essentially identical results were obtained in three other independent experiments.
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ /PKC but also is a potent activator of this kinase in vitro. The addition of LIP plus phosphatidylserine together did not produce any additive or synergistic effect (not shown). To determine whether this is also true in vivo, quiescent Cos cells were transfected with either HA-/PKC or HA-PKC and were simultaneously cotransfected with either an empty plasmid or an expression plasmid for LIP, after which they were stimulated with serum for 5 min, and both transfected PKCs were recovered with anti-HA antibody. Interestingly, expression of LIP dramatically activated /PKC but not PKC in vivo to an extent comparable to that produced by serum (Fig. 8) . The same stimulation was observed when /PKC and LIP were transfected into NIH 3T3 cells (results not shown). Taken together, these results indicate that LIP is a novel protein capable of specifically and directly binding to the atypical /PKC isoform both in vitro and in vivo, which leads to its specific activation. Transactivation of a B-dependent promoter by LIP. Since the activation by overexpression of /PKC leads to the transactivation of B-dependent promoters (7) (Fig. 1) , transfection of a LIP expression vector should conceivably be able to activate that reporter plasmid. Results in Fig. 9 demonstrate that the transfection of a LIP expression vector promotes a dramatic activation of a B-dependent promoter to an extent similar to that produced by TNF-␣ (7). Interestingly, cotransfection of a /PKC expression plasmid significantly synergizes with LIP to transactivate the B-reporter plasmid (Fig. 10) .
Conversely, transfection of a kinase-inactive dominant negative mutant of /PKC severely impairs the activation of the B promoter by LIP (Fig. 10) . However, transfection of the kinase-inactive dominant negative mutant of PKC does not produce any effect on the stimulation of that promoter by LIP (not shown). All the above data indicate that the activation by LIP of /PKC in vivo is physiologically relevant.
DISCUSSION
PKCs form a large family of lipid-activable kinases that play pivotal roles in cell signalling. The so-called classical or conventional PKCs are critically involved in cell processes associated with the generation of increased cytosolic Ca 2ϩ levels and diacylglycerol (32) , such as those produced by the activation of the phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-P 2 (32) . More recently, increased interest has been focused on the understanding of the functional role, as well as the mechanisms that regulate the novel and atypical PKC isoforms. Both kinds of PKC subtypes have been implicated in the control of key cellular events such as cell proliferation. Thus, overexpression of the novel εPKC leads to increased cell growth whereas overexpression of ␦PKC provokes the opposite effect (26, 32) . Regarding the atypical PKC isotypes, it has been recently demonstrated that the microinjection of a peptide with the sequence of the pseudosubstrate of these isoforms dramatically inhibits oocyte maturation (10), cell proliferation (3), and NF-B activation (11) . The pseudosubstrate region of PKC is identical to that of /PKC but is significantly different from that of conventional and novel PKCs (32), indicating that either or both atypical isoforms are important in cell signalling. The recent report of the sequence of /PKC as a distinct atypical isotype (1, 38) has allowed the identification of the previously cloned X. laevis PKC isoform as actually /PKC. Inhibition of /PKC by antisense oligonucleotides (10) or by transfection or microinjection of a kinase-inactive dominant negative mutant (3, 7, 9 ) produced a severe reduction of important cell signalling parameters such as the stimulation of the B-dependent promoter activity (4, 7) . We show here that transfection of kinase-inactive mutants of either /PKC or PKC severely impaired the activation of a Bdependent promoter. Also, the overexpression of the wild-type genes of either atypical isotypes activated this reporter construct. This is a reliable and sensitive biological readout of the mitogenic and inflammatory responses. Although both isotypes similarly regulate the B-promoter activity, /PKC constructs were significantly more potent than PKC constructs were (Fig.  1) . The fact that the two kinases displayed comparable behavior at high concentrations ( Fig. 1) was to some extent predictable from the identity of their catalytic domains. Although the major differences between the atypical isoforms are located in their regulatory regions, both isotypes are activated by ceramide with similar kinetics and both bind Ras in vitro with identical affinity (23) . Therefore, we reasoned that if functional differences underlay the sequence divergences existing in the regulatory domain of the two atypical isotypes, this could more probably be unveiled by the molecular characterization of hy- (40) . Also, the characterization of another class of PKC-binding proteins, collectively termed RACKs, has been reported (27, 35) . Interestingly, they appear to be important for the subcellular localization of activated classical PKC subspecies, a process that seems critical for their functionality in vivo (27, 35) . One of the most remarkable aspects of LIP is that it activates /PKC most probably by directly binding to the kinase zinc finger-like domain, a region thought to be stimulated only by lipids and their pharmacological analogs (32, 34) . From the data presented here, the zinc finger domain of the PKCs should be considered a site for activation of these enzymes, not only by lipids but also FIG. 7. Activation of /PKC but not PKC by LIP in vitro. Cos cells were transfected with either control plasmid or expression vectors for HA-tagged PKC or /PKC, after which they were made quiescent by serum starvation, and the expressed proteins were immunoprecipitated with an anti-HA antibody, as described in Materials and Methods. The effect of 1 g of MBP, 1 g of MBP-LIP(R4), or phosphatidylserine (PS) (50 g/ml) on regulation of the enzymatic activity of HA-PKC or HA/PKC was determined. The two kinases were expressed at identical levels (not shown). Essentially identical results were obtained in another two experiments.
FIG. 8. Activation of /PKC but not PKC by LIP in vivo. Cos cells were transfected with either control plasmid or expression vectors for HA-PKC or HA-/PKC along with either control plasmid (CMV) or a LIP(R4) expression vector, after which they were made quiescent by serum starvation and were either untreated or stimulated with 10% serum for 10 min. Then the HA-tagged PKCs were immunoprecipitated and their activity was determined as described in Materials and Methods. The two kinases were expressed at identical levels (not shown). Essentially identical results were obtained in another two experiments.
FIG. 9. Transfection of a LIP expression vector is sufficient to transactivate a B-dependent promoter. Cos cells were transfected with different concentrations of plasmid CMV-LIP(R4) along with 500 ng of the B enhancer-directed luciferase reporter plasmid (3EconALuc). After 4 h, the DNA-containing medium was removed and cells were made quiescent by serum starvation for 24 h. Then extracts were prepared and the luciferase activity was determined as described in Materials and Methods. As a control, cells transfected with empty plasmid were stimulated with TNF-␣ (500 U/ml) for 4 h (open bar). Results are the mean Ϯ SD of three independent experiments with incubations in duplicate.
by functionally relevant regulatory proteins. Actually, a very recent report shows that the zinc finger domain of εPKC serves to localize this isoform to the Golgi apparatus (21) . Whether this has a functional repercussion in the activity of εPKC deserves further investigation. Since LIP binds to /PKC but not PKC, one can speculate on the existence of distinct LIP-like proteins specific for the different PKC isotypes. If further work confirms this model, it will mean that the specificity for the activation of the different PKC isoforms cannot be totally accounted for by lipid mediators but that specific PKC zinc finger-binding proteins are most probably also involved. This implies a change in the way we have so far envisioned the mechanism of PKC regulation.
